List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8978607/publications.pdf Version: 2024-02-01

124 papers	24,102 citations	471371 17 h-index	23514 111 g-index
127 all docs	127 docs citations	127 times ranked	40550 citing authors

#	Article	IF	CITATIONS
1	Successful Use of High Dose Methotrexate in Treatment of Primary CNS Lymphoma Patients Without Access to Serum Methotrexate Levels Monitoring: Challenges and Outcome. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 68-77.	0.3	5
2	The success rate of interphase fluorescence in situ hybridization in plasma cell disorders can be improved using unconventional sources of plasma cells. International Journal of Laboratory Hematology, 2022, 44, 157-162.	0.7	2
3	Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India. Blood Cancer Journal, 2022, 12, 2.	2.8	7
4	Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e685-e690.	0.2	10
5	Short Research Communication Anti-Spike Antibody Response to COVISHIELDâ,,¢ (SII-ChAdOx1 nCoV-19) Vaccine in Patients with B-Cell and Plasma Cell Malignancies and Hematopoietic Cell Transplantation Recipients. Indian Journal of Hematology and Blood Transfusion, 2022, 38, 745-749.	0.3	4
6	Cyclophosphamide, hydroxycyclophosphamide and carboxyethyl phosphoramide mustard quantification with liquid chromatography mass spectrometry in a single run human plasma samples: A rapid and sensitive method development. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2022, 1198, 123228.	1.2	3
7	Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 626-634.	0.2	7
8	Dual peaks on flow cytometric <scp>DNA</scp> ploidy analysis in chronic lymphocytic leukemia with <scp>Richter</scp> transformation. Cytometry Part B - Clinical Cytometry, 2022, 102, 323-325.	0.7	1
9	Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study. Leukemia and Lymphoma, 2022, 63, 2679-2685.	0.6	3
10	Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 114-118.	0.6	3
11	Efficacy, safety, and quality of life of generic and innovator ibrutinib in Indian CLL patients. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 313-317.	0.3	3
12	Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL. Leukemia and Lymphoma, 2021, 62, 1674-1681.	0.6	4
13	Does Mesenchymal Stromal Cell Count in Pre-autologous Hematopoietic Stem Cell Transplant Peripheral Blood and Apheresis Product Predict for Infectious Complications in the Post-transplant Period?. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 484-488.	0.3	0
14	Graft versus host disease localized to striae distensae: An example of locus minoris resistentiae. Indian Journal of Dermatology, Venereology and Leprology, 2021, 87, 1-3.	0.2	1
15	Autosomal dominant familial periodic fever patient with a missense variant c.215G>A (p.Cys72Tyr) in TNFRSF1A gene presenting as neutrophilia. European Journal of Medical Genetics, 2021, 64, 104191.	0.7	0
16	Role of preâ€transplant chest highâ€resolution computed tomography and serum galactomannan index in predicting postâ€transplant invasive pulmonary aspergillosis in allogeneic hematopoietic cell transplant recipients. Transplant Infectious Disease, 2021, 23, e13632.	0.7	3
17	Detection of c.755T>C; p.L265P/c.751C>T;p.264R/* compound heterozygous MYD88 mutation in a case of Waldenstrom macroglobulinemia. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 702-704.	0.3	0
18	Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort. Annals of Hematology, 2021, 100, 2031-2041.	0.8	3

#	Article	IF	CITATIONS
19	The frequency and clinico-hematological characteristics of gain(1q21) positive myeloma in an Indian cohort. Leukemia Research, 2021, 105, 106577.	0.4	1
20	Health-related quality of life in transplant eligible multiple myeloma patients with or without early ASCT in the real-world setting. Leukemia and Lymphoma, 2021, 62, 3271-3277.	0.6	5
21	Aberrant expression of cytokines in polycythemia vera correlate with the risk of thrombosis. Blood Cells, Molecules, and Diseases, 2021, 89, 102565.	0.6	6
22	Impact of broadâ€spectrum antibiotic exposures and multidrugâ€resistant gramâ€negative bacteremia on hematopoietic cell transplantation outcomes. Transplant Infectious Disease, 2021, 23, e13717.	0.7	3
23	TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India. BMC Gastroenterology, 2021, 21, 327.	0.8	15
24	Bendamustine in combination with ifosfamide, etoposide, and vinorelbine (VIBE) is an effective salvage regimen for heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma: a single-center experience. Blood Research, 2021, 56, 134-140.	0.5	2
25	A look inside the body of a BCR-ABL1-like acute lymphoblastic leukemia patient: the first case report highlighting the continued relevance of autopsy practice. Blood Research, 2021, , .	0.5	0
26	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia, 2021, 35, 3444-3454.	3.3	57
27	Covid-19 Infection in Hematological Malignancies: Registry Data from India. Blood, 2021, 138, 1938-1938.	0.6	0
28	Detection of Double Hit and Triple Hit Cytogenetics at Relapse Identifies a Very High Risk Subset of Relapsed/Refractory Multiple Myeloma Patients. Blood, 2021, 138, 2706-2706.	0.6	0
29	An Unusual Case of Fungating Chest Wall Mass. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 211-212.	0.3	0
30	Randomized controlled trial of twice-daily versus alternate-day oral iron therapy in the treatment of iron-deficiency anemia. Annals of Hematology, 2020, 99, 57-63.	0.8	34
31	Resolution of high output pulmonary edema due to hyperviscosity with plasma exchange in a patient with multiple myeloma- a case report. Transfusion and Apheresis Science, 2020, 59, 102898.	0.5	0
32	Waldenström Macroglobulinemia of the orbit: A diagnostic challenge. European Journal of Ophthalmology, 2020, , 112067212096345.	0.7	2
33	Carfilzomib-induced thrombotic microangiopathy: A case based review. Hematology/ Oncology and Stem Cell Therapy, 2020, , .	0.6	8
34	Quality of life in patients of chronic lymphocytic leukemia using the EORTC QLQ 30 and QLQ LL17 questionnaire. European Journal of Haematology, 2020, 105, 755-762.	1.1	24
35	Making sense of cross-trial comparisons for the frontline treatment of advanced-stage Hodgkin lymphoma. European Journal of Cancer, 2020, 136, 113-115.	1.3	1
36	Hematopoietic stem cell donor with IgA nephropathy: Challenges and management algorithm. Transfusion and Apheresis Science, 2020, 59, 102781.	0.5	1

#	Article	IF	CITATIONS
37	Poor tolerability to ponatinib in Indian CML patients. Blood Advances, 2020, 4, 1927-1929.	2.5	1
38	Still learning the right way to administer melphalan in autologous transplantation. Bone Marrow Transplantation, 2020, 55, 2357-2358.	1.3	1
39	A systematic review of economic evaluations of treatment regimens in multiple myeloma. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 21, 1-11.	0.7	2
40	Butter in blood:Âhypertriglyceridemia secondary to pegylated. QJM - Monthly Journal of the Association of Physicians, 2020, 113, 898-898.	0.2	2
41	Ponatinibâ€induced lamellar ichthyosisâ€like eruption. International Journal of Dermatology, 2020, 59, e156-e157.	0.5	9
42	How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?. Indian Journal of Hematology and Blood Transfusion, 2020, 36, 605-615.	0.3	9
43	Chronic Lymphocytic Leukemia: Real-World Data From India. JCO Global Oncology, 2020, 6, 866-872.	0.8	15
44	Doseâ€adjusted EPOCHâ€R: a feasible alternative for Burkitt lymphoma in resourceâ€constrained settings. British Journal of Haematology, 2020, 190, e362-e363.	1.2	2
45	Variables affecting the presence of mesenchymal stromal cells in peripheral blood and their relationship with apheresis products. British Journal of Haematology, 2020, 189, 772-776.	1.2	7
46	Caution: PET-CT in plasma cell disorders. Lancet Haematology,the, 2020, 7, e95.	2.2	1
47	Modified CLL International Prognostic Index (CLL-LIPI) using lymphocyte doubling time (LDT) in place of IgHV mutation status in resource-limited settings predicts time to first treatment and overall survival. Leukemia and Lymphoma, 2020, 61, 1512-1515.	0.6	9
48	Therapeutic whole blood exchange in the management of methaemoglobinemia: Case series and systematic review of literature. Transfusion Medicine, 2020, 30, 231-239.	0.5	13
49	Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016. Occupational and Environmental Medicine, 2020, 77, 151-159.	1.3	64
50	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1459-1468.	2.0	35
51	An unusual presentation of Richter's transformation of chronic lymphocytic leukemia in liver and lung on ¹⁸ F-labeled fluoro-2-deoxyglucose positron emission tomography/computed tomography. Indian Journal of Nuclear Medicine, 2020, 35, 70.	0.1	4
52	Genomic alterations in chronic lymphocytic leukemia and their correlation with clinico-hematological parameters and disease progression. Blood Research, 2020, 55, 131-138.	0.5	8
53	Deluging Thrombosis: An Unusual Presentation of Acute Promyelocytic Leukemia. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 282-284.	0.1	1
54	Clinical Research in Hematology‑Oncology in India during the COVID-19 Era. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 799-800.	0.1	0

#	Article	IF	CITATIONS
55	Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplantation, 2019, 54, 2088-2095.	1.3	16
56	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. JAMA Oncology, 2019, 5, 1749.	3.4	1,691
57	Clinicopathological Profile of Myelomatous Pleural Effusion: Single-center Real-world Experience and Review of Literature. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 183-189.e1.	0.2	17
58	Poor Mobilisation After Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple Myeloma. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 584-586.	0.3	6
59	Haemorrhagic Bulla: A Rare Presentation of Acute Lymphoblastic Leukemia. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 369-370.	0.3	1
60	Chronic Myeloid Leukemia Presenting with Fleeting Facial Nerve Palsy. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 371-372.	0.3	2
61	Intra-Abdominal Pseudotumors: A Rare Presentation of Von Willebrand Disease and its Management in Resource Constraint Setting. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 390-391.	0.3	1
62	Evaluating the role of Tregs in the progression of multiple myeloma. Leukemia and Lymphoma, 2019, 60, 2134-2142.	0.6	20
63	Reduced Dose Ibrutinib Due to Financial Toxicity in CLL. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 260-264.	0.3	7
64	Immune Thrombocytopenia is Still the Commonest Diagnosis on Consultative Hematology. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 352-356.	0.3	6
65	Corpus Callosum Bleed: A Rare Presentation of Acute Promyelocytic Leukemia. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 384-386.	0.3	1
66	Multiple Granulocytic Sarcomas: A Rare Presentation of Acute Myeloid Leukemia. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 186-188.	0.3	1
67	Adolescent and Young Adult Chronic Myeloid Leukemia in Real-World Settings: Experience from a Tertiary Care Institute in Northern India. Journal of Adolescent and Young Adult Oncology, 2019, 8, 94-97.	0.7	6
68	Real world experience with "generic―pomalidomide in relapsed refractory multiple myeloma. Leukemia and Lymphoma, 2019, 60, 1102-1104.	0.6	8
69	"Blueberry Muffin Spots―in an Adult Male Successfully Treated with Imatinib. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 174-175.	0.3	3
70	Early detection of differentiation syndrome by chest ultrasound in acute promyelocytic leukaemia. British Journal of Haematology, 2019, 184, 672-673.	1.2	4
71	CML patients presenting with priapism: Is there any disparity in outcome?. Journal of Clinical Oncology, 2019, 37, e18545-e18545.	0.8	3
72	Methotrexate and mucositis: A merry-go-round for oncologists. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 150-152.	0.1	2

#	Article	IF	CITATIONS
73	Outcome of CML patients with de novo bleeding complications: Do they behave differently?. Journal of Clinical Oncology, 2019, 37, e18546-e18546.	0.8	1
74	Individualized, Low Dose, Fixed Duration Lenalidomide Maintenance Is an Effective Strategy in High MRD Disease Post Chemo-Immunotherapy in CLL: Outcomes of a Randomized Controlled Trial. Blood, 2019, 134, 5471-5471.	0.6	0
75	Fertility Management for the Hemato-Oncologist. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 13-18.	0.3	2
76	Balanitis in Acute Lymphoblastic Leukemia: A Rare Etiology and Unusual Presentation. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 546-548.	0.3	1
77	Necrotising Ulcerative Gingivitis: A Rare Manifestation of Pseudomonas Infection. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 578-580.	0.3	8
78	Danazol increases T regulatory cells in patients with aplastic anemia. Hematology, 2018, 23, 496-500.	0.7	9
79	Invasive Fungal Infections in Acute Promyelocytic Leukemia on Dual Differentiating Agents: Real World Data. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 466-468.	0.3	5
80	Longâ€ŧerm mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients. International Journal of Dermatology, 2018, 57, 332-338.	0.5	15
81	Regulatory T-cells drive immune dysfunction in CLL. Leukemia and Lymphoma, 2018, 59, 486-489.	0.6	15
82	Analysis of Clinical Profile and Outcome of Tuberculosis in Patients with Acute Leukemia. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 430-442.	0.3	15
83	AYA-Myeloma: Real-World, Single-Center Experience Over Last 5 Years. Journal of Adolescent and Young Adult Oncology, 2018, 7, 120-124.	0.7	18
84	Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 261-267.	0.3	19
85	Infusion Related Hypersensitivity Reactions with Bio-similar Anti CD-20 Monoclonal Antibody Rituximab in Indian Patients: A Retrospective Study. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 273-277.	0.3	6
86	Cost of Treatment of Multiple Myeloma in a Public Sector Tertiary Care Hospital of North India. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 25-31.	0.3	22
87	Variation in Adherence Measures to Imatinib Therapy. Journal of Global Oncology, 2018, 4, 1-10.	0.5	2
88	Impact of bisphosphonate and anti-myeloma therapy on bone turnover markers in multiple myeloma. Annals of Oncology, 2018, 29, viii370.	0.6	0
89	Goitre, lymphoma and the doughnut sign. BMJ Case Reports, 2018, 2018, bcr-2018-226581.	0.2	2
90	A comparative study of 18F-FDG PET/CT with bilateral bone marrow trephine biopsy for assessment of bone marrow infiltration by lymphoma. Annals of Oncology, 2018, 29, viii362.	0.6	0

#	Article	IF	CITATIONS
91	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	6.3	4,989
92	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	6.3	3,269
93	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	6.3	8,569
94	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	6.3	335
95	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	6.3	2,123
96	Assessment of bleeding risk by sonoclot in acute lymphoblastic leukemia. Annals of Oncology, 2018, 29, viii370.	0.6	0
97	Establishment of a comprehensive chronic lymphocytic leukemia clinic at a tertiary referral center in India. Blood Advances, 2018, 2, 33-34.	2.5	7
98	Hemophilia in the developing world: transforming lives through international collaboration. Blood Advances, 2018, 2, 39-41.	2.5	4
99	Global Burden of Multiple Myeloma. JAMA Oncology, 2018, 4, 1221.	3.4	398
100	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	6.3	638
101	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. JAMA Oncology, 2018, 4, 1553.	3.4	1,260
102	Diffuse Large B-Cell Lymphoma: A Rare Cause of Lung Consolidation. Indian Journal of Hematology and Blood Transfusion, 2018, 34, 768-771.	0.3	1
103	Cost and complications are limitations in resourceâ€constrained settings for equine antiâ€ŧhymocyte globulin. European Journal of Haematology, 2018, 101, 421-421.	1.1	1
104	A quintessential syndrome with a rare marvelling aetiology: Rosai-Dorfman disease presenting as Conus-Cauda syndrome. BMJ Case Reports, 2018, 2018, bcr-2017-222398.	0.2	2
105	Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference. Indian Journal of Hematology and Blood Transfusion, 2017, 33, 15-21.	0.3	11
106	Bullous Pyoderma Gangrenosum Associated with Hairy Cell Leukemia and Its Complete Response to Cladribine Therapy. Indian Journal of Hematology and Blood Transfusion, 2017, 33, 273-275.	0.3	4
107	Use of Surrogate Samples to Monitor pH During High dose Methotrexate Therapy. Indian Journal of Hematology and Blood Transfusion, 2017, 33, 188-194.	0.3	1
108	Complications and management of coagulation disorders in leukemia patients. Blood and Lymphatic Cancer: Targets and Therapy, 2017, Volume 7, 61-72.	1.2	11

#	Article	IF	CITATIONS
109	Acute promyelocytic leukaemia: looking through â€~gums'. BMJ Case Reports, 2016, 2016, bcr2016217457.	0.2	2
110	Successful Allogeneic Hematopoietic Cell Transplantation Using Flu-Bu-ATG Conditioning for "Mono-MAC Syndrome―[GATA2 Deficiency]. Biology of Blood and Marrow Transplantation, 2016, 22, S333.	2.0	1
111	Pre-Transplant Vitamin D Deficiency is Associated with Inferior Overall Survival but not Associated with Relapse Free Survival or Cumulative Incidence of GVHD Post Adult Hematopoietic Cell Transplantation for Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, S334.	2.0	1
112	Peri-anal Paraneoplastic Pemphigus Heralding the Relapse of Follicular Lymphoma and Its Successful Management by Rituximab: A Short Correspondence. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 519-521.	0.3	5
113	CLL: Common Leukemia; Uncommon Presentations. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 268-275.	0.3	3
114	FDG PET/CT in the staging and follow-up of primary cardiac †T' cell lymphoma presenting as hypertrophic cardiomyopathy. Journal of Nuclear Cardiology, 2016, 23, 581-584.	1.4	6
115	Real World Experience of Clinical Profile and Outcomes of Autoimmune Hemolytic Anemia: Single Centre Experience. Blood, 2016, 128, 4814-4814.	0.6	0
116	Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias. Leukemia and Lymphoma, 2015, 56, 2424-2428.	0.6	39
117	Pyrexia, Lung nodules, Granulomas: Pulmonary Lymphomatoid Granulomatosis. Indian Journal of Hematology and Blood Transfusion, 2014, 30, 418-421.	0.3	4
118	Outcomes of splenectomy versus cladribine for hairy cell leukemia in resource limited settings. Leukemia and Lymphoma, 2014, 55, 1428-1430.	0.6	3
119	Short Response Duration to Initial Treatment of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 5665-5665.	0.6	2
120	Infections Are a Major Cause of Prolongation of Hospital Stay in Hematopoietic Stem Cell Transplants in Tropical, Developing Countries: Profile of a Transplant Center in North India. Blood, 2014, 124, 5853-5853.	0.6	1
121	Chronic Lymphocytic Leukemia: Inception to Cure: Are We There?. Indian Journal of Hematology and Blood Transfusion, 2013, 29, 1-10.	0.3	5
122	Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. Leukemia and Lymphoma, 2013, 54, 1012-1019.	0.6	42
123	Hematopoietic Stem Cell Applications: Past, Present and Future. Journal of Postgraduate Medicine Education and Research, 2012, 46, 69-74.	0.1	0
124	Do Regulatory T Cells Have a Role in Disease Progression and Autoimmune Cytopenias of Chronic Lymphocytic Leukemia?,. Blood, 2011, 118, 3864-3864.	0.6	2